TY - JOUR
T1 - Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial
AU - Smit, Amelia K.
AU - Allen, Martin
AU - Beswick, Brooke
AU - Butow, Phyllis
AU - Dawkins, Hugh
AU - Dobbinson, Suzanne J.
AU - Dunlop, Kate L.
AU - Espinoza, David
AU - Fenton, Georgina
AU - Kanetsky, Peter A.
AU - Keogh, Louise
AU - Kimlin, Michael G.
AU - Kirk, Judy
AU - Law, Matthew H.
AU - Lo, Serigne
AU - Low, Cynthia
AU - Mann, Graham J.
AU - Reyes-Marcelino, Gillian
AU - Morton, Rachael L.
AU - Newson, Ainsley J.
AU - Savard, Jacqueline
AU - Trevena, Lyndal
AU - Wordsworth, Sarah
AU - Cust, Anne E.
N1 - Funding Information:
The study was funded by an National Health and Medical Research Council (NHMRC) project grant (1129822) and CRE (1135285), and endorsed by Melanoma and Skin Cancer Trials (ANZMTG 03.17). A.K.S. received a Research Training Program (RTP) Stipend Scholarship and a Merit Top Up Scholarship from the University of Sydney, and a Melanoma Institute Australia Postgraduate Research Scholarship. R.M. is funded by a NHMRC of Australia TRIP Fellowship (1150989) and University of Sydney Robinson Fellowship. P.B. is funded by an NHMRC Senior Principal Research Fellowship (1121630). K.L.D. receives a NHMRC Postgraduate Research Scholarship (1191336), NHMRC Supplementary Scholarship 2020 from the University of Sydney and The Erik Mather PhD Scholarship (Melanoma Institute Australia). A.E.C. is funded by a Career Development Fellowship from the NHMRC (1147843). No funding sources had any involvement in the study design, data collection, analysis, interpretation, publication, nor approval of the manuscript.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Purpose: We evaluated the impact of personal melanoma genomic risk information on sun-related behaviors and psychological outcomes. Methods: In this parallel group, open, randomized controlled trial, 1,025 Australians of European ancestry without melanoma and aged 18–69 years were recruited via the Medicare database (3% consent). Participants were randomized to the intervention (n = 513; saliva sample for genetic testing, personalized melanoma risk booklet based on a 40-variant polygenic risk score, telephone-based genetic counseling, educational booklet) or control (n = 512; educational booklet). Wrist-worn ultraviolet (UV) radiation dosimeters (10-day wear) and questionnaires were administered at baseline, 1 month postintervention, and 12 months postbaseline. Results: At 12 months, 948 (92%) participants completed dosimetry and 973 (95%) the questionnaire. For the primary outcome, there was no effect of the genomic risk intervention on objectively measured UV exposure at 12 months, irrespective of traditional risk factors. For secondary outcomes at 12 months, the intervention reduced sunburns (risk ratio: 0.72, 95% confidence interval: 0.54–0.96), and increased skin examinations among women. Melanoma-related worry was reduced. There was no overall impact on general psychological distress. Conclusion: Personalized genomic risk information did not influence sun exposure patterns but did improve some skin cancer prevention and early detection behaviors, suggesting it may be useful for precision prevention. There was no evidence of psychological harm.
AB - Purpose: We evaluated the impact of personal melanoma genomic risk information on sun-related behaviors and psychological outcomes. Methods: In this parallel group, open, randomized controlled trial, 1,025 Australians of European ancestry without melanoma and aged 18–69 years were recruited via the Medicare database (3% consent). Participants were randomized to the intervention (n = 513; saliva sample for genetic testing, personalized melanoma risk booklet based on a 40-variant polygenic risk score, telephone-based genetic counseling, educational booklet) or control (n = 512; educational booklet). Wrist-worn ultraviolet (UV) radiation dosimeters (10-day wear) and questionnaires were administered at baseline, 1 month postintervention, and 12 months postbaseline. Results: At 12 months, 948 (92%) participants completed dosimetry and 973 (95%) the questionnaire. For the primary outcome, there was no effect of the genomic risk intervention on objectively measured UV exposure at 12 months, irrespective of traditional risk factors. For secondary outcomes at 12 months, the intervention reduced sunburns (risk ratio: 0.72, 95% confidence interval: 0.54–0.96), and increased skin examinations among women. Melanoma-related worry was reduced. There was no overall impact on general psychological distress. Conclusion: Personalized genomic risk information did not influence sun exposure patterns but did improve some skin cancer prevention and early detection behaviors, suggesting it may be useful for precision prevention. There was no evidence of psychological harm.
UR - http://www.scopus.com/inward/record.url?scp=85112675601&partnerID=8YFLogxK
U2 - 10.1038/s41436-021-01292-w
DO - 10.1038/s41436-021-01292-w
M3 - Article
C2 - 34385669
AN - SCOPUS:85112675601
SN - 1098-3600
VL - 23
SP - 2394
EP - 2403
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 12
ER -